
Medivation has argued that Sanofi’s offer fails to value fairly the prospects of its recently developed prostate cancer drug XTANDI,…
Combiflam is a combination of paracetamol and ibuprofen, and is one of Sanofi’s five biggest brands in India.
1 million students from 6,000 public schools to begin dengue vaccinations this year The first public dengue immunisation programme has…
Agreement expands Merial portfolio to include 15 new products, making it a key player in the dairy cattle market in…
Research collaboration and licensing agreement for new bispecific antibodies will use Innate Pharma’s and Sanofi’s technology to target tumour cells…
With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue prevention tool…
First marketing authorization of Dengvaxia is a historic milestone paving the way to significantly impact dengue burden in endemic countries…
To develop immuno-oncology pills Sanofi is teaming up with Germany’s Evotec and Austrian biotech firm Apeiron Biologics to develop a…
He will take the position as Executive Vice President and External Affairs Sanofi appointed Suresh Kumar as a new member…
Patent applications for pain treatments between 2008 and 2012 were dominated by Big Pharma, including Sanofi, Novartis and Merck &…
Both Apollo and Sanofi would endeavour to expand Apollo Sugar to provide superior value to patients and doctors with an…
Apollo Hospitals intends to launch 500 Apollo Sugar Clinics by 2019-end in India and overseas to spread network of diabetes…
In September this year, Apollo Hospitals and Sanofi joined hands to set up Sugar Clinics for diabetics. With 65 million…
The launch of Shan5 vaccine receives pre-qualification status from the World Health Organization
Drugmaker Sanofi Pasteur has announced the world’s first dengue vaccine could come in the second half of 2015.
Dengue has been a serious challenge to public health as it affects lakhs of people annually in India.